



Contacts: Tran Nguyen / CFO
Somaxon Pharmaceuticals, Inc.
(858) 480-0400

Rob Whetstone
PondelWilkinson Inc.
(310) 279-5963

**SOMAXON PHARMACEUTICALS TO REPORT FIRST QUARTER 2010 RESULTS
AND TO CONDUCT CONFERENCE CALL ON TUESDAY, MAY 11, 2010**

SAN DIEGO, CA – May 3, 2010 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its first quarter 2010 financial results on Tuesday, May 11, 2010 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the first quarter 2010.

The conference call will be available to interested parties through a live audio Internet broadcast at <http://investors.somaxon.com/eventdetail.cfm>. The call will also be archived and accessible at this site for approximately two weeks. Alternatively, callers may participate in the conference call by dialing (877) 941-8610 (domestic) or (480) 629-9819 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international), and entering passcode 4291482.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's product Silenor[®] (doxepin) has been approved by the FDA for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the company's web site at www.somaxon.com.

###